The Swiss Life Sciences Group was founded to capitalise on the flourishing and ever-evolving cannabis and cannabidiol (CBD) industry, which is currently the fastest-growing sector in Holistic Healthcare and wellness solutions.
The Swiss Life Sciences Group is a producer of premium organic CBD and phytocannabinoid medical products, with production, manufacturing and certification across the EU. Our strategy is to carefully build The Swiss Life Sciences Group through a series of strategic investments, joint ventures, mergers and acquisitions into one of Europe’s largest seed-to-consumer, vertically integrated business models.
Since 2019 the group has been focused on diligent research and analysis-led decisions, leading to establishing production, processing and manufacturing in the world’s newest and largest single CBD market – Switzerland and the EU.
Our strategy, after building asset value, distribution and real business, is a two-stage listing in London. Firstly, listing on the dynamic Aquis exchange within the next 12 months, followed by a full London Stock Exchange listing within the next four years.